FDA cuts back on fast drug approval

Expedited drug approvals slowed this year as the Food and Drug Administration's contentious accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency's own leaders.

Related Keywords

United States ,Washington ,Robert Califf ,Reshma Ramachandran ,Mike Sherman ,Sam Kay ,Yale University ,Drug Administration ,Congress Do ,